This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stephan, C. Articles by Loening, S. A. Search for Related Content PubMed PubMed Citation Articles by Stephan, C. Articles by Loening, S. A.

Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer¹

Department of Urology [C. S., K. J., M. L., D. S., S. A. L.] and Institute of Laboratory Medicine and Pathological Biochemistry [P. S.], University Hospital Charité, Humboldt University Berlin, D-10098 Berlin, Germany

Prostate-specific antigen (PSA) is the most useful marker in the early detection of prostate cancer and for the monitoring of patients with this diagnosis. Molecular forms of PSA and also human kallikrein 2 have been used to discriminate between benign prostatic hyperplasia and prostate cancer as well as for the detection of prostate cancer within the gray zone of PSA. In this respect, a literature survey on the diagnostic validity of free PSA (fPSA) related to total PSA (tPSA), PSA bound to ₁-antichymotrypsin (ACT-PSA), and complexed PSA is given together with our results. The ratio of fPSA:tPSA has been shown to improve the specificity of prostate cancer diagnosis on the basis of tPSA measurements. Unnecessary biopsies can be reduced by about 19–64% in the total PSA range of 4–10 µg/liter while only missing 5–10% of cancers. Furthermore, carcinomas in patients with PSA values <4 µg/liter can be detected, indicating an improved sensitivity because of the percent fPSA at low PSA values. ACT-PSA or complexed PSA alone and the calculated derivatives are not superior in their discriminatory power compared with the percent fPSA. The diagnostic significance of the other molecular PSA forms and human kallikrein 2 needs to be evaluated in more extensive clinical trials.

This article has been cited by other articles:

				K. A. Shaikh, K. S. Ryu, E. D. Goluch, J.-M. Nam, J. Liu, C. S. Thaxton, T. N. Chiesl, A. E. Barron, Y. Lu, C. A. Mirkin, et al. A modular microfluidic architecture for integrated biochemical analysis PNAS, July 12, 2005; 102(28): 9745 - 9750. [Abstract] [Full Text] [PDF]

				C. A. Borgono, I. P. Michael, and E. P. Diamandis Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280. [Abstract] [Full Text] [PDF]

				A. Michael, C. Stephan, D. Schnorr, S. A. Loening, and K. Jung Serum Macrophage Migration Inhibitory Factor Is Not Elevated in Patients with Prostate Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2004; 13(2): 328 - 329. [Full Text] [PDF]

				C. A. Borgono, L. Grass, A. Soosaipillai, G. M. Yousef, C. D. Petraki, D. H. C. Howarth, S. Fracchioli, D. Katsaros, and E. P. Diamandis Human Kallikrein 14: A New Potential Biomarker for Ovarian and Breast Cancer Cancer Res., December 15, 2003; 63(24): 9032 - 9041. [Abstract] [Full Text] [PDF]

				T. Nakamura, A. Scorilas, C. Stephan, K. Jung, A. R. Soosaipillai, and E. P. Diamandis The Usefulness of Serum Human Kallikrein 11 for Discriminating between Prostate Cancer and Benign Prostatic Hyperplasia Cancer Res., October 1, 2003; 63(19): 6543 - 6546. [Abstract] [Full Text] [PDF]

				G. M. Yousef, M.-E. Polymeris, L. Grass, A. Soosaipillai, P.-C. Chan, A. Scorilas, C. Borgono, N. Harbeck, B. Schmalfeldt, J. Dorn, et al. Human Kallikrein 5: A Potential Novel Serum Biomarker for Breast and Ovarian Cancer Cancer Res., July 15, 2003; 63(14): 3958 - 3965. [Abstract] [Full Text] [PDF]

				S. Wesseling, C. Stephan, A. Semjonow, M. Lein, B. Brux, P. Sinha, S. A. Loening, and K. Jung Determination of Non-{alpha}1-Antichymotrypsin-complexed Prostate-specific Antigen as an Indirect Measurement of Free Prostate-specific Antigen: Analytical Performance and Diagnostic Accuracy Clin. Chem., June 1, 2003; 49(6): 887 - 894. [Abstract] [Full Text] [PDF]

				R. Peracaula, G. Tabares, L. Royle, D. J. Harvey, R. A. Dwek, P. M. Rudd, and R. de Llorens Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins Glycobiology, June 1, 2003; 13(6): 457 - 470. [Abstract] [Full Text] [PDF]

				S. Hutchinson, L.-Y. Luo, G. M. Yousef, A. Soosaipillai, and E. P. Diamandis Purification of Human Kallikrein 6 from Biological Fluids and Identification of its Complex with {alpha}1-Antichymotrypsin Clin. Chem., May 1, 2003; 49(5): 746 - 751. [Abstract] [Full Text] [PDF]

				S. P. Balk, Y.-J. Ko, and G. J. Bubley Biology of Prostate-Specific Antigen J. Clin. Oncol., January 15, 2003; 21(2): 383 - 391. [Abstract] [Full Text] [PDF]

				C. Kapadia, A. Chang, G. Sotiropoulou, G. M. Yousef, L. Grass, A. Soosaipillai, X. Xing, D. H.C. Howarth, and E. P. Diamandis Human Kallikrein 13: Production and Purification of Recombinant Protein and Monoclonal and Polyclonal Antibodies, and Development of a Sensitive and Specific Immunofluorometric Assay Clin. Chem., January 1, 2003; 49(1): 77 - 86. [Abstract] [Full Text] [PDF]

				T. Kishi, L. Grass, A. Soosaipillai, C. Shimizu-Okabe, and E. P. Diamandis Human Kallikrein 8: Immunoassay Development and Identification in Tissue Extracts and Biological Fluids Clin. Chem., January 1, 2003; 49(1): 87 - 96. [Abstract] [Full Text] [PDF]

				C. Stephan, H. Cammann, A. Semjonow, E. P. Diamandis, L. F.A. Wymenga, M. Lein, P. Sinha, S. A. Loening, and K. Jung Multicenter Evaluation of an Artificial Neural Network to Increase the Prostate Cancer Detection Rate and Reduce Unnecessary Biopsies Clin. Chem., August 1, 2002; 48(8): 1279 - 1287. [Abstract] [Full Text] [PDF]